Live-Attenuated Vaccine Against Chikungunya Virus Highly Immunogenic Across Age Groups, Phase III Trial Results Suggest

November 23, 2021

MedPage Today (11/21, Walker) reported that “a live-attenuated vaccine against mosquito-borne chikungunya virus was highly immunogenic across age groups, with no serious safety concerns,” according to topline results from a phase III trial presented “at t...